lets get real, page-4

Does lead us to the next logical question why are we letting fonda approval hold the Phase 3 trial back?

Should we be dipping our hands in our pockets to get things cracking? He who dares wins mentality?

Little bit from Nektar summary re NKTR-102

"Market Overview
NKTR-102 is in Phase 2 clinical development for patients with solid tumor malignancies, including colorectal, breast, ovarian and cervical cancers. Each year, approximately 3 million patients worldwide are diagnosed with one of these types of cancer. Irinotecan revolutionized the treatment of colorectal cancer in 1996 but its utility has been limited by poor pharmacokinetics and lack of development.

NKTR-102 Clinical Data and Product Profile
NKTR-102 is a topoisomerase I inhibitor-polymer conjugate with a unique pharmacokinetics profile that provides a continuous concentration of active drug with reduced peak concentrations. NKTR-102 was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform. Irinotecan is an important chemotherapeutic agent used in the treatment of colorectal cancer. However, standard irinotecan is typically cleared from the body within a few hours of dosing, resulting in a lower tumor exposure to the active metabolite that may limit its efficacy. Clinical and preclinical studies with NKTR-102 have been shown to increase the life and exposure profiles relative to irinotecan, resulting in significant anti-tumor activity. These data suggest that an improved form of irinotecan with a superior half-life and pharmacokinetics/pharmcodynamics profile could improve outcomes for patients whose cancers are typically treated with this chemotherapeutic agent".

http://www.nektar.com/product_pipeline/oncology_nktr-102.html